RedHill Biopharma (RDHL) Gross Profit (2014 - 2023)

RedHill Biopharma (RDHL) has reported Gross Profit for 9 consecutive years, with $990000.0 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Gross Profit fell 89.41% year-over-year to $990000.0 in Q2 2023; TTM through Jun 2023 was $15.3 million, a 51.16% decrease from a year earlier, with the FY2025 full-year figure at $5.5 million, up 13.67% from the prior year.
• Gross Profit was $990000.0 for Q2 2023 at RedHill Biopharma, down from $2.0 million in the prior quarter.
• Over five years, Gross Profit peaked at $12.4 million in Q3 2021 and troughed at -$659000.0 in Q1 2020.
• A 5-year average of $5.5 million and a median of $5.5 million in 2020 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit slumped 149.92% in 2020 and surged 1666.31% in 2021, its largest moves.
• Over 5 years, Gross Profit stood at $802000.0 in 2019, then surged by 1247.76% to $10.8 million in 2020, then slumped by 74.68% to $2.7 million in 2021, then soared by 53.45% to $4.2 million in 2022, then slumped by 76.43% to $990000.0 in 2023.
• The last three Gross Profit figures came in at $990000.0 (Q2 2023), $2.0 million (Q1 2023), and $4.2 million (Q4 2022), per Business Quant data.